You would like to read
- IMPRESSION Randomized Trial: Past the halfway mark and progressing rapidly
- Merck Foundation provides 100 new Cardiovascular preventive experts to mark World Heart Day 2021 in 25 countries in Africa and Asia
- Merck Foundation marks World Diabetes Day 2021 by training over 600 doctors in diabetes, preventative cardiovascular, and endocrinology
- STL delivers Cloud-Native OSS/BSS solution powered by Microsoft Azure
- International Business education and cultural immersion: critical to professional growth
Milano (Italy) [India], January 28 (ANI/PR Newswire): FONDAZIONE Ricerca e Innovazione Cardiovascolare, Milano, focused on cardiovascular research, reports the first patient enrolment of the (https://www.conceptmedical.com/press-release/transform-ii) TRANSFORM II Randomized Controlled Trial (Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels) setting in motion a crucial trial in the Native Coronary Vessel Treatment domain.
TRANSFORM II RCT, determined to explore and evaluate the treatment options in native coronary vessels, enrolled the index patient on the 16 December 2021 at Sandro Pertini Hospital, Rome, by the team of Dr Alessandro Sciahbasi.
The International, multicentric, prospective, investigator-driven, open-label randomized trial will observe and evaluate the efficacy of the (https://www.conceptmedical.com/product/magic-touch) Magic Touch Sirolimus Coated Balloon (https://www.conceptmedical.com) Concept Medical Inc.) in a head-to-head comparison with Everolimus-Eluting Stent (EES) considered to be a gold standard treatment, in 1:1 randomization in the native coronary vessels. This trial is led by Study Chairman, Dr Bernardo Cortese of the San Carlo Clinic, Paderno Dugnano-Milano, Italy. Alongside him in the steering committee are Dr Roxana Mehran, Dr Alexandre Abizaid, Dr Stefano Rigattieri, Dr Fernando Alfonso, Dr Jose Maria de la Torre Hernandez and Dr Peter Smith.
The idea of intervention in small or mid-sized de-novo coronary lesion with a stent is neither desirable nor efficient, considering the heavy metal scaffolding of the vessel. Newer generation of interventionalists tend to be hesitant to load the vessel with a metal scaffold in this setting. Drug-Coated Balloons (DCB) therefore offer a better option while treating native coronary artery lesions.
A total of 1325 patients will be enrolled. The study population will consist of patients with age & gt;18 years with clinical indication of a native vessel PCI eligibility (stable CAD or Acute coronary syndrome). Native coronary artery lesion in a vessel with diameter & gt;2.0 mm and
DISCLAIMER
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
